Premium
Renal Transplantation in HIV‐Infected Patients: The Paris Experience
Author(s) -
Touzot M.,
Pillebout E.,
Matig M.,
Tricot L.,
Viard J. P.,
Rondeau E.,
Legendre C.,
Glotz D.,
Delahousse M.,
Lang P.,
Peraldi M. N.
Publication year - 2010
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2010.03258.x
Subject(s) - medicine , tacrolimus , transplantation , calcineurin , trough level , kidney transplantation , incidence (geometry) , adverse effect , gastroenterology , kidney disease , surgery , urology , optics , physics
Kidney transplantation is now considered as a reasonable option for HIV‐infected patients with end‐stage renal disease. We describe here a retrospective study conducted in five transplantation centers in Paris. Twenty‐seven patients were included. Immunosuppressive protocol associated an induction therapy and a long‐term treatment combining mycophenolate mofetil, steroids and either tacrolimus or cyclosporine. All the patients had protocol biopsies at 3 months and 1 year. Patient's survival was 100% at 1 year and 98% at 2 years. Graft survival at 1 and 2 years is 98% and 96% at 1 and 2 years, respectively. The mean glomerular filteration rate values at 12 and 24 months were 60.6 mL/min/1.73 m 2 (range 23–98) and 65.4 mL/min/1.73m 2 (range 24–110), respectively. Acute cellular rejection was diagnosed in four cases (15%). Because of high trough levels of calcineurin inhibitor, protease‐inhibitor therapies were withdrawn in 11 cases. HIV disease progression was not observed. One patient developed B‐cell lymphoma.In conclusion, our study confirms the safety of renal transplantation in HIV‐infected patients with few adverse events and a low incidence of acute rejection.